AstraZeneca PLC American Depositary Shares (AZN)
NASDAQ (NGS) NASDAQ (NGS) Primary 
AstraZeneca lung cancer therapy combination shows promise in advanced study
AstraZeneca said on Tuesday that a Chinese late-stage trial of a combination of its cancer drugs Tagrisso and Orpathys significantly improved progression-free survival when given as a first-line treatment for a type of lung cancer.
AZN/AMGN's Tezspire Hits Primary Goal in Eosinophilic Esophagitis Study
AstraZeneca's Tezspire delivers positive CROSSING data in EoE, meeting all primary and secondary endpoints and supporting its expansion potential.
Oncology Stocks to Add to Your Portfolio as Cancer Care Evolves
Oncology innovation is driving new treatment options, with Iovance, Merit Medical and Kura advancing cancer-focused therapies and technologies.
AstraZeneca drug succeeds in trial for swallowing disorder
AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) said its drug Tezspire worked in a late-stage trial of patients with eosinophilic esophagitis, a chronic condition that inflames the gullet and makes swallowing difficult. The drug, developed with the American biotech company Amgen, hit both of its main goals and every important secondary one.
AstraZeneca's asthma drug Tezspire meets all goals in late-stage esophagitis trial
AstraZeneca said on Thursday its asthma drug, Tezspire, developed with Amgen , met its main and secondary goals in a late-stage trial for treating eosinophilic esophagitis, a chronic inflammatory disorder of the esophagus.
AstraZeneca prices €2.55bn euro bond sale across four tranches
AstraZeneca PLC (LSE:AZN, NASDAQ:AZN), the FTSE 100 pharma group, has priced a €2.55 billion bond offering, tapping the euro debt market for general corporate purposes. The notes were issued on Monday by AstraZeneca Finance LLC, a wholly owned US subsidiary, and carry a full and unconditional guarantee from the parent company.
BioMarin Inks $490M Deal to Buy Rare Bone Disease Treatment
BMRN's $490M Alesta deal adds ALE1, a potential oral HPP therapy, broadening its rare bone disease portfolio and clinical pipeline.
AstraZeneca Vs. Bristol-Myers Squibb: Who's The Better Bargain For Investors?
Rumors of an AstraZeneca PLC-Bristol-Myers Squibb Company merger are cooling, yet each company's standalone strength deserves closer scrutiny. Overall, AZN and BMY occupy leading positions in the cancer and immune-mediated inflammatory diseases markets. Each of them has advantages, as well as dark spots in the portfolio of drugs relative to the rival.
AZN Ends NSCLC Study for Bispecific Antibody Over Unlikely Success
AstraZeneca halts a phase III NSCLC study for volrustomig after data show that the regimen is unlikely to meet key survival goals, while other lung cancer trials shine.
AstraZeneca maintains Citi 'buy' rating despite mixed pipeline updates
AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) has retained a 'buy' rating from Citi following a mixed set of pipeline updates, with the broker saying its underlying investment thesis remains unchanged and that the drugmaker continues to offer the strongest growth and pipeline profile in the sector. Citi highlighted positive results from the Phase III SAFFRON trial, where Tagrisso plus Orpathys met the primary endpoint and demonstrated statistically significant and clinically meaningful progression-free survival and overall survival benefits against platinum-doublet chemotherapy in second-line EGFR-mutated, MET-driven non-small cell lung cancer.
AstraZeneca lung cancer drug combination extends survival in trial
AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) has reported positive results from a late-stage trial of a two-drug combination for a hard-to-treat form of lung cancer, potentially opening the way to approval around the world. The study tested the company's established lung cancer pill Tagrisso alongside a newer drug called Orpathys, developed with the Hong Kong-based biotech HUTCHMED.
AstraZeneca Ends Phase Three Lung Cancer Drug Trial After Review
The decision was based on the recommendation of the Independent Data Monitoring Committee, which said volrustomig plus chemotherapy was unlikely to reach primary endpoints.
